Try Ask OE! Our NEW Advanced AI Enabled Search Dive into the Largest Database of Musculoskeletal Evidence Ask OE

ACE Reports.

+ Filters
Make a selection below to explore our full database of 9 results matching: "IR Reid"
ACE Reports
(9 Reports)
ACE Reports
Our Al driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Close Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
to
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
to
ACE Report Image
Metabolic Disorders
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
ACE Report Image
Osteoarthritis
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
J Bone Miner Res. 2015 May;30(5):934-44.
ACE Report Image
Metabolic Disorders
Antiresorptive effects of single zoledronate dose are sustained for 3 years
J Bone Miner Res. 2010 Oct;25(10):2251-5
ACE Report Image
Metabolic Disorders
Five-year follow-up of the effects of calcium supplementation in postmenopausal women
Osteoporos Int. 2014 Jan;25(1):297-304. doi: 10.1007/s00198-013-2526-z. Epub 2013 Oct 10.
ACE Report Image
General Orthopaedics
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.
ACE Report Image
Spine
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292
ACE Report Image
General Orthopaedics
The effect of 3 versus 6 years of zoledronic acid treatment on femoral neck-BMD
J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494
ACE Report Image
General Orthopaedics
Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9
ACE Report Image
General Orthopaedics
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Denosumab reduces risk of fractures in post-menopausal women
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Help us Improve

Provide additional feedback (optional)

Submit Feedback

Thank You!

Thank you for providing valuable feedback regarding your recent interaction with Ask OE.

Return to Ask OE